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22q11.2 microduplications of a 3-Mb region surrounded by low-copy repeats should be, theoretically, as frequent
as the deletions of this region; however, few microduplications have been reported. We show that the phenotype
of these patients with microduplications is extremely diverse, ranging from normal to behavioral abnormalities to
multiple defects, only some of which are reminiscent of the 22q11.2 deletion syndrome. This diversity will make
ascertainment difficult and will necessitate a rapid-screening method. We demonstrate the utility of four different
screening methods. Although all the screening techniques give unique information, the efficiency of real-time poly-
merase chain reaction allowed the discovery of two 22q11.2 microduplications in a series of 275 females who
tested negative for fragile X syndrome, thus widening the phenotypic diversity. Ascertainment of the fragile X–
negative cohort was twice that of the cohort screened for the 22q11.2 deletion. We also report the first patient
with a 22q11.2 triplication and show that this patient’s mother carries a 22q11.2 microduplication. We strongly
recommend that other family members of patients with 22q11.2 microduplications also be tested, since we found
several phenotypically normal parents who were carriers of the chromosomal abnormality.
Chromosomal rearrangements of 22q11.2 result in
several genomic disorders, including the 22q11.2 dele-
tion syndrome (also known as “DiGeorge syndrome”
[MIM 188400] and “velocardiofacial syndrome” [MIM
192430]), and partially overlapping duplications result
in cat eye syndrome (CES [MIM 115470]) and der(22)
syndrome (reviewed by McDermid and Morrow [2002])
(fig. 1). These rearrangements are thought to be the re-
sult of nonallelic homologous recombination between
low-copy repeats found in the region (LCR22s) (Edel-
mann et al. 1999b; Stankiewicz and Lupski 2002). In
particular, the 22q11.2 deletion syndrome represents the
most commonly ascertained deletion syndrome in hu-
mans, with a frequency estimated at 1/4,000–6,000 live
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births (Shaffer and Lupski 2000; Botto et al. 2003). Fea-
tures of the 22q11.2 deletion syndrome include cleft pal-
ate, velopharyngeal insufficiency, hypernasal speech,
characteristic facial features, heart defects, learning dis-
abilities, and behavioral disorders (Shprintzen et al.
1978; Swillen et al. 1999). More-severely affected pa-
tients may have a reduced or absent thymus, as well as
hypocalcemia (DiGeorge 1965). Since this microdeletion
results from unequal crossing over—usually between the
LCR22s separated by 3 Mb and usually on different
chromosome 22 homologues (Saitta et al. 2004)—one
would expect the reciprocal 3-Mb microduplication of
the region to be present with a frequency equal to that
of the 22q11.2 deletion. However, there are few reports
of microduplications of this region of 22q11.2 (Edel-
mann et al. 1999b; Papenhausen et al. 2002; Ensenauer
et al. 2003; Hassed et al. 2004). A small number of
patients with larger duplications that include the critical
regions for both CES and 22q11.2 deletion syndrome
have also been reported (Reiss et al. 1985; Knoll et al.
1995; Lindsay et al. 1995), but these patients have fea-
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Figure 1 Duplications and deletions on chromosome 22q11.2. Arrows indicate the size of the various deletions and duplications. Triangles
below the line representing the chromosome show the location of the LCR22s. Probes located above the line were used in the various FISH
and dosage techniques.
tures typical of CES. These duplications also overlap
with critical regions in patients with der(22) syndrome,
who have partial trisomy for the 22pter-q11 regions,
including half of the region typically deleted in 22q11.2
deletion syndrome (Funke et al. 1999; Kurahashi et al.
2000) (fig. 1). Similarly, Smith-Magenis syndrome (SMS)
is a microdeletion syndrome associated with 17p11.2
(Smith et al. 1986) and is characterized by mental re-
tardation, neurobehavioral abnormalities, sleep disor-
ders, speech and motor delays, midface hypoplasia, short
stature, and brachydactyly. The reciprocal microdupli-
cation of 17p11.2 has only recently been identified. It
has a phenotype that is milder than that of the deletion
(Potocki et al. 2000), including behavioral problems,
mild-to-borderline mental retardation, short stature,
dental anomalies, normal facies, and a lack of major-
organ malformations.
Microduplications of 22q11.2 may be largely unde-
tected, as a result of a less-distinct, unpredictable, and/
or milder phenotype, which leads not only to problems
with ascertainment and choosing the patient cohort to
search but also to technical difficulties involved in iden-
tifying microduplications. A recent report described the
clinical, cytogenetic, and molecular findings of 10 in-
dependent patients with 22q11.2 microduplications. Se-
ven of the microduplications include only the 22q11.2
deletion syndrome region (Ensenauer et al. 2003). These
individuals were ascertained from 653 patients tested
for the 22q11.2 deletion; the latter syndrome was diag-
nosed in 40 of 653 patients. The patients with 22q11.2
microduplications had a variable phenotype, including
heart defects, velopharyngeal insufficiency with and with-
out cleft palate, hearing loss, growth delay, cognitive
deficits, motor delay, learning disabilities, behavioral
problems, and mild dysmorphic features. Whereas the
phenotype of some individuals with a 22q11.2 micro-
duplication may overlap with that of individuals with
the 22q11.2 deletion syndrome, this overlap may (as a
result of ascertainment bias) represent only one part of
this syndrome’s phenotypic spectrum. If these reciprocal
chromosomal rearrangements are of equal frequency,
then the difference in frequency between patients with
22q11.2 deletion syndrome (6.1%) and those with
22q11.2 microduplications (1.5%) in the test group used
by Ensenauer et al. (2003) indicates that the majority of
patients with microduplications do not fall within this
test group.
In this report, we present seven unrelated patients/
families (one reported elsewhere [Edelmann et al. 1999b])
with increased copy number in the 22q11.2 deletion
syndrome region. Table 1 compares the clinical features
of these patients with the features of patients published
elsewhere. Figure 2 illustrates features of two patients.
The microduplications in patients 1–5 were originally
Table 1
Clinical Characterization of Eight Patients with Increased Dosage of 22q11.2
FEATURE
FINDING FOR PATIENT
RESULTS
(NO. AFFECTED/
NO. TESTED)
OF ENSENAUER
ET AL. (2003)1 2 3 4 4M 5 6 7
22q11.2 copy number 3 3 3 4 3 3 3 3
Age at last evaluation 8 years 4 years 1 mo 8 years 4 mo 3 years 34 years
Sex M F M F F F F F
Heart defect   a  b   2c,d/6
Velopharyngeal insufficiency      5/5
Palatal defect A     4/7
Hearing impairment e   e  f  4/6
Failure to thrive       
Sleep apnea   
Absent thymus/asplenia       1/6
Urogenital abnormality       2/5
Hypotonia        1/5
Gastrointestinal abnormality      
Cognitive deficits g,h g,h g,i h i 5/5
Behavioral problems j k  l 3/3
Seizures     1/6
Dysmorphic features: 6/6
Broad nasal bridge    
Hand/foot abnormality m n o o    4p,q/5
Hypertelorism   
Epicanthal folds   2/5
Micrognathia     3/5
Microcephaly    1/6
Additional features r s t u v w 6/6
Other x y z aa bb
NOTE.—“” p feature present; “” p feature absent; blank cells indicate unknown or patient too young to determine; A p
arched.
a Hypoplastic left heart.
b Tetrology of Fallot and right-sided aortic arch.
c Tetrology of Fallot.
d Hypoplastic left heart and interrupted aortic arch.
e Impairment secondary to recurrent otitis media.
f Mild conductive deafness.
g Speech delay.
h Developmental delay.
i Learning difficulties.
j Impulsivity and aggression.
k Short concentration span and social immaturity.
l Childhood aggression and childhood ADD.
m Clinodactyly of the fifth fingers.
n Hypoplastic fifth fingernail and toenails smaller than normal.
o Broad hands, with square tipped fingers and prominent fetal finger pads.
p Abnormal palmar creases.
q Long fingers and/or toes.
r High forehead, round face, flat supraorbital ridge, short nose, thin upper lip, and long, smooth philtrum.
s Narrow face and downslanting palpebral fissures.
t Prominent eyes, medial deficiency of the eyebrows, and prominent chin and lower lip.
u Eversion of the lateral eye lids and bulbous nasal tip.
v Facial asymmetry.
w Mild synophrys, tented peak in the middle of each eyebrow, facial asymmetry, and small, downslanting mouth.
x Maternal half brother (aged 16 years) with developmental delay, paternal cousin (aged 9 years) with behavioral problems, and
another paternal cousin with cleft lip and palate.
y Gross motor delay and poor fine-motor skills.
z Nystagmus and myopia; prominent metopic suture, with an anterior fontanel of a width of three fingers; sagittal sutures widely
separated; and open posterior fontanel.
aa Left ear pit.
bb Chorioretinal coloboma, visual impairment, and preauricular skin tags.
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Figure 2 Photographs of patients with increased dosage of
22q11.2. A, Patient 1. B, Patient 4. C, Hands of patient 4 and her
mother (patient 4M). The unlabeled hand is an unaffected sister of
patient 4.
identified during tests for the 22q11.2 deletion syndrome
at five different centers. Patients 6 and 7 were ascertained
by screening 275 female patients referred for diagnostic
fragile X syndrome testing. The seven patients show a
remarkable variation in phenotype, with some showing
little-to-no resemblance to the phenotype of 22q11.2 de-
letion syndrome.
Most patients in this study were analyzed by several
different methods to confirm an increased copy number
within 22q11.2. Patients 1–5 were originally identified
by FISH. Analysis of interphase nuclei of patients 1 and
3 showed a microduplication of the Vysis TUPLE1
probe (fig. 3A [patient 1]). To narrow the extent of mi-
croduplication, cells from patient 1 were further tested
using a number of BAC clones (obtained from the Well-
come Trust Sanger Institute and M. Rocchi) within and
surrounding the 22q11.2 deletion syndrome region.
Probes proximal (109L3, N54G12, and BK154H4) and
distal (BA24N11, BCR, and BA297B9) to the 22q11.2
deletion syndrome region were not duplicated. Only
probes D22S75/N25 and TUPLE1, located within the
22q11.2 deletion syndrome region, were duplicated. Du-
plications of the 22q11.2 deletion syndrome region were
shown in patient 2 by use of Oncor probe N25 (Edel-
mann et al. 1999b). Interphase FISH analysis was per-
formed on patient 4 with the use of two BAC probes
located within the 22q11.2 deletion syndrome region.
Probe 361L10 (green) was clearly triplicated and showed
four hybridization spots (fig. 3B), whereas 901P22 (red)
gave ambiguous results (three copies in most cells, but
four copies in some cells [see fig. 3B]). Analysis could not
be repeated, as a result of a lack of sample. The consistent
clustering of three of the four copies of 361L10 indicates
the presence of three copies on one chromosome 22 and
one copy on the other homologue. FISH on interphase
nuclei of patient 5 showed three TUPLE1 (red) signals,
compared with two ARSA (green) signals (fig. 3C). On
review of signals for metaphase chromosomes, a TUPLE1
signal on one chromosome 22 was subjectively larger
(fig. 3D), supporting a tandem duplication of this re-
gion, rather than a cryptic translocation. FISH studies
of the parents of patient 5 revealed the same microdu-
plication in the infant’s father, who was healthy but had
a history of significant learning difficulties, unilateral
hearing loss, and poor vision in one eye. No FISH anal-
ysis was done for patients 6 and 7.
The triplication in patient 4 was analyzed using the
microsatellite marker D22S1709, which is located in the
distal portion of the 22q11.2 deletion syndrome region
(fig. 1). Four different alleles are present at this locus,
confirming four copies of the region (fig. 4). This probe
is located within BAC 901P22, which gave ambiguous
FISH results of three or four copies. The microsatellite
analysis confirms the involvement of four different chro-
mosome 22 homologues in the production of this trip-
lication. Microsatellite analyses were also done on pa-
tients 3, 5, 6, and 7. Several loci within the 22q11.2
deletion syndrome region were informative for the pres-
ence of three distinct alleles in all four patients (results
not shown).
Since it is cumbersome, expensive, and labor-intensive
to screen for 22q11.2 interstitial microduplications by
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Figure 3 FISH analyses. A, Patient 1 test probe TUPLE1 (red) shows three copies for an interphase cell; control probe ARSA (green)
shows two copies. B, Patient 4 test probes 361L10 and 901P22 (green and red, respectively) show four copies for this cell. C, Patient 5 test
probe TUPLE1 (red) shows three copies; control probe ARSA (green) shows two copies. D, Metaphase spread from patient 5 shows the
duplication of the TUPLE1 probe.
use of interphase FISH, we sought a more efficient
screening method. Real-time PCR analysis of two genes
in the proximal 1.5 portion (fig. 1) of the 22q11.2 de-
letion syndrome region (HIRA and COMT) was per-
formed on all patients (fig. 5) with the use of a multi-
plexed array of two quantitative reactions (Thiel et al.
2003). A TaqMan GJA5 gene Pre-Developed Assay Re-
agent (PDAR [Applied Biosystems]) was multiplexed as
a two-copy control in both reactions. Reactions from
patients with 22q11.2 deletion syndrome, from wild-
type DNA, and from “no template” controls were in-
cluded in each analysis. All real-time PCR amplifications
were performed on an ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems) with the use of
a 384-well plate. HIRA and COMT were assayed in
separate reactions, and each assay was performed in trip-
licate. Sequence Detection Software (SDS, version 2.0
[Applied Biosystems]) was used to process raw fluores-
cence data and to produce a threshold cycle number (Ct)
for each sample. The Ct value was the cycle number at
which the fluorescence emission of the reporter dye
passed a fixed threshold on the amplification plot. The
default setting for the threshold was 10 SDs above the
mean baseline emission. All Ct settings were manually
checked and adjusted within the logarithmic curve be-
tween background and plateau levels. The ABI 7900 HT
data were exported to a Microsoft Excel macro in which
all Ct values were normalized to the multiplexed PDAR
and were compared with the wild-type and positive-con-
trol values.
Patients 1, 2, 3, and 5 have three copies of HIRA and
COMT, indicating a microduplication of the 22q11.2
deletion syndrome region of 22q11.2. Patient 4 was
found to have four copies of HIRA and COMT, con-
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Figure 4 Microsatellite analysis of probe D22S1709, showing four different alleles in patient 4, with sizes (in bp) marked below the
peaks. Unmarked peaks are due to stutter bands, an artifact of PCR. The method has been described elsewhere (Edelmann et al. 1999a).
firming a triplication of the 22q11.2 deletion syndrome
region. Interestingly, the mother of patient 4 (patient
4M) was found to have only three copies of 22q11.2,
indicating an expansion of the 22q11.2 deletion syn-
drome region from three to four copies between mother
and child. This was confirmed cytogenetically. In addi-
tion to FISH analysis, patients 3 and 5 were indepen-
dently ascertained by real-time PCR among 671 22q11.2
deletion syndrome referrals (0.3%). In this same cohort,
26 cases of 22q11.2 deletion were detected (3.9%).
The efficiency of the real-time PCR analysis allowed
us to quickly screen for microduplications in a set of
275 unrelated females who were negative for fragile X
syndrome; the individuals in this set were collected from
multiple referrals, with little or no clinical data available.
However, since common features of patients with the
22q11.2 microduplication are behavioral and cognitive
problems, the fragile X–negative cohort would be a rea-
sonable group to screen. Only females were screened, to
minimize the contribution of X-linked conditions to the
analysis. Our screen resulted in the discovery of two
patients (0.7%) with duplications in the 22q11.2 dele-
tion syndrome region (fig. 5 [patients 6 and 7]). Per-
mission from the Health Research Ethics Board of the
University of Alberta Health Sciences Faculties allowed
us to access the clinical data for these two patients (table
1). As controls, 520 unrelated individuals referred for
hemochromatosis testing were also screened for micro-
duplication of 22q11.2. None of the control individuals
had a microduplication of 22q11.2 ( ), indi-P ! .00003
cating that this chromosomal abnormality is not a poly-
morphism. Interestingly, one patient (0.4%) in the fragile
X–negative female group had a deletion of 22q11.2.
Although real-time PCR allowed the rapid analysis
of a large number of individuals, it did not allow us to
define the size of the microduplication, since only two
probes in the 22q11.2 deletion syndrome region were
examined. Sizing of microduplications requires the ex-
amination of multiple sites along 22q11.2, which is ex-
pensive to set up for real-time PCR and is time-consum-
ing to test by FISH and microsatellites. We therefore
analyzed the patients by use of our CES/22q11.2 dele-
tion syndrome multiplex amplifiable probe hybridiza-
tion (MAPH) probe set that covered regions both distal
and proximal to the 22q11.2 deletion syndrome region
(table 2). Seven probes were located within the CES re-
gion, one probe was within the 3-Mb 22q11.2 deletion
syndrome region (ZNF74 [position 19073420 bp in
the UCSC Genome Browser May 2004 Assembly Map]),
and one probe was ∼600 kb distal to the 22q11.2 de-
letion syndrome region (SDF2L1 [position 20321160
bp in the UCSC Genome Browser May 2004 Assembly
Map]) (fig. 1). Control probes, supplied by J. Armour
(University of Nottingham), were located on other chro-
mosomes (5, 15, 16, and 17). In addition to patient DNA
samples, three control samples were used: the two-copy
control was a normal lymphoblast cell line GM03657
(Coriell Institute for Medical Research); the three-copy
control was a lymphoblastoid cell line from a patient
with a duplication including the CES region and the
22q11.2 deletion syndrome region (Reiss et al. 1985;
McDermid et al. 1986; H.E.M., unpublished results);
and the four-copy control was patient CM01, who has
CES and is known to have four copies of both the CES
region and the 22q11.2 deletion syndrome region (Mc-
Taggart et al. 1998). Genescan software was used to
calculate the peak area for each probe. Peak ratios were
calculated by dividing the peak area of a test probe by
the sum of the peak areas of the two closest control
probes. Each experiment contained four to eight repli-
cates of the two-copy control, the three-copy control,
and a patient. Each peak-ratio replicate for all samples
was normalized to the mean peak ratio of the two-copy
control. The mean and SD of the normalized peak ratios
for each probe were calculated for the two-copy control,
the three-copy control, and the patient. One experiment
also contained a four-copy control.
A graph of the normalized mean peak ratio (1 SD)
for each probe, compared with a two-copy and three-
copy control, was plotted for patients 1–4 (fig. 6), as
well as for patient 6 and the mother of patient 4 (data
for the latter two not shown). DNA was not available
for MAPH analysis of patients 5 and 7. A four-copy
control was included for patient 4. In all cases, a ratio
of ∼1:1 with the two-copy control was calculated for
all the probes within the CES region and distal to the
22q11.2 deletion syndrome region, indicating no dupli-
cation of these probes. Thus, in each patient tested, the
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Figure 5 Real-time PCR analysis of probes COMT and HIRA (also known as “TUPLE1”). Copy number was calculated by multiplying
the DDCt ratio by 2. A two-copy control was run for each set of experiments, but only the most variable two-copy control is shown in each
graph. Error bars represent 1 SD above and below the mean. Each reaction mixture consisted of 200 nmol/L of each primer, 50 nmol/L of
TaqMan probe, 40 ng of genomic DNA, 0.3 ml of PDAR (Applied Biosystems), and 7.5 ml of 2# TaqMan mix (Applied Biosystems), in a total
volume of 15 ml. Thermal cycling conditions included a presoak for 2 min at 50C and for 10 min at 95C. Samples were amplified for 40
cycles at 95C for 15 s and at 60C for 1 min.
region of increased dosage was confined to the 22q11.2
deletion syndrome region, and no cases extended prox-
imally, as in the study by Ensenauer et al. (2003). The
size of the duplication could not be determined for pa-
tients 5 and 7. In all cases, the previous results showing
microduplications and triplications were confirmed. On
the basis of the ratios calculated for the ZNF74 probe
(∼1.5:1 with the two-copy control), patients 1, 2, 3, and
6 have a microduplication of the 22q11.2 deletion syn-
drome region. In each experiment, the three-copy control
showed a ratio of ∼1.5:1 with the two-copy control. In
patient 4 and the four-copy control, a ratio of ∼2:1 with
the two-copy control was calculated for ZNF74, con-
firming that patient 4 has a triplication of the 22q11.2
deletion syndrome region. The mother of patient 4 (pa-
tient 4M) was confirmed to have three copies of ZNF74
(data not shown).
In summary, we report seven unrelated patients/fam-
ilies with duplication or triplication of the 3-Mb 22q11.2
deletion syndrome region. Ensenauer et al. (2003) de-
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Table 2
MAPH Probes, Primer Sequences, and Sizes
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 6 MAPH analysis of the 22q11.2 region for patients 1, 2, 3, and 4. Probes are shown below the four graphs and are listed in
order along the chromosome (centromere at left), with the CES region and the 22q11.2 deletion syndrome region indicated. Normalized mean
peak ratios (error bars represent 1 SD above and below the mean) are graphed for all probes for each patient (unblackened triangles connected
by a line) and control (two-copy control sample represented by blackened diamonds; three-copy control sample represented by squares). The
four-copy control sample (circles) has four copies of the CES region and the 22q11.2 deletion syndrome region; however, distal to the 22q11.2
deletion syndrome region, the copy number is 2. Probes and probe mixes, membrane preparation, and hybridization were performed in accordance
with the study by Armour et al. (2000) and the Multiplex Amplifiable Probe Hybridization (MAPH) Web site, with the following changes.
Genomic DNA was blotted onto a Hybond N membrane (Amersham Biosciences). After hybridization, the membranes were washed six times
for 10 min each at 65C in 1# SSC/1% SDS solution and six times for 10 min each at 65C in 0.1# SSC/0.1% SDS solution. Membranes
were each placed in a 0.2-ml PCR tube with 50 ml of 1# AB gene buffer IV and were heated to 95C to release the probes; 3.75 ml of this
solution was used as a template for a fluorescent PCR containing 1# AB gene buffer IV, 2 mM MgCl2, 0.4 mM dNTPs, 2 mM PZA-FAM, 1
mM PZB, and 2.5 U Taq polymerase (Invitrogen). Finally, 1 ml of the PCR was mixed with 1 ml of formamide loading dye, and 1.2 ml of the
mixture was run on a polyacrylamide gel for 3.5 h by use of the ABI Prism 377 DNA sequencer.
scribed seven unrelated patients with just the 22q11.2
deletion syndrome region duplicated, as well as an ad-
ditional three independent patients with duplications
that included the 22q11.2 deletion syndrome region and
extended distally. All were ascertained from 653 patients
referred for 22q11.2 deletion testing. Although distinct
dysmorphic features for the microduplication were sug-
gested, the other features of the seven patients have a
strong bias toward 22q11.2 deletion syndrome features,
including conotruncal heart defects (2/6), velopharyn-
geal insufficiency (5/5), cleft palate (4/7), cognitive de-
fects (5/5), and absent thymus with T-cell deficiency (1/
6). This is not surprising, considering the method of
ascertainment. However, although our patients 1–5 were
also identified through 22q11.2 deletion testing, they
show a less distinct phenotype, with fewer instances of
velopharyngeal insufficiency (1/4) and no cases of cleft
palate or abnormal thymus. Developmental/speech de-
lay, behavioral problems, and mild dysmorphic features
are the major phenotypes observed in our patients 1–5
(table 1). Aggressive behavior and attention deficit dis-
order (ADD) were seen in patients from both studies.
The true spectrum of 22q11.2 microduplication syn-
drome will not be apparent until patients are ascertained
independently of the 22q11.2 deletion syndrome symp-
toms. We have initiated this by screening 275 females
who were referred for diagnostic fragile X syndrome
testing but with no FMR1 expansion detected. We iden-
tified two patients with 22q11.2 microduplications in
this group and no microduplications in 520 controls
( ). Patient 6 showed an eye defect, as well asP ! .00003
dysmorphic features and developmental delay, but her
phenotype did not particularly resemble that of 22q11.2
deletion syndrome. In fact, the presence of a coloboma
and preauricular tags in this patient suggested an as-
sociation with the CES duplication, yet the CES critical
region was not duplicated. Patient 7 showed only be-
havioral symptoms, with no similarity to the 22q11.2
deletion syndrome. The analysis of these patients sug-
gests that a large number of individuals with 22q11.2
microduplications do not show similarity to 22q11.2
deletion syndrome and, therefore, are currently undi-
agnosed, which would explain the imbalance between
reported deletions and duplications of this region. The
lack of similarity of our patients to each other under-
scores the remarkable variability in the phenotype of this
syndrome, which will make ascertainment of the ma-
jority of cases extremely difficult.
A significant number of 22q11.2 microduplications
may also be associated with a normal phenotype. The
mother and grandmother of patient 2 both carry the mi-
croduplication and are normal (Edelmann et al. 1999b).
The mother of patient 4 shows a normal phenotype,
except for her hands, but has a 22q11.2 microduplica-
tion. The father of patient 5 has the microduplication
and showed learning difficulties and hearing loss. This
suggests that parents of children with 22q11.2 dupli-
cations should also be tested for the same microdupli-
cation, since it could be responsible for other mild ab-
normalities within the pedigree and is a potential risk
to future children of the parents and of other relatives.
The normal or near-normal phenotype associated with
a significant proportion of patients with 22q11.2 mi-
croduplications could also explain why there appears to
be no correlation between patients with CES with in-
creased dosage of the 22q11.2 deletion syndrome region
and those without increased dosage, in addition to trip-
lication of the CES region (McTaggart et al. 1998). Since
the sample size of patients with CES was small (10 in-
dividuals) and the phenotype of CES is highly variable,
small additions to the phenotype from microduplication
or triplication of the 22q11.2 deletion syndrome region
may not be detectable unless a very large number of
patients are analyzed. Interstitial duplications includ-
ing both the CES and the 22q11.2 deletion syndrome
regions have also shown predominantly CES-like fea-
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tures (Reiss et al. 1985; Knoll et al. 1995; Lindsay et al.
1995).
Patient 4 has a triplication of the 22q11.2 deletion
syndrome region, which has been confirmed by four in-
dependent methods (figs. 3, 4, 5, and 6). To our knowl-
edge, this is the first reported triplication of the 22q11.2
deletion syndrome region. Microsatellite analysis of pa-
tient 4 showed the presence of four different alleles of
locus D22S1709, located in the distal portion of the
22q11.2 deletion syndrome region. This implies that
four different chromosome 22 homologues were in-
volved in the creation of the triplication. FISH analysis
showed that the two extra copies are on the same chro-
mosome. This could be explained by an interchromo-
somal exchange in a maternal heterozygous grandpar-
ent—which would have created the microduplication in
the mother—followed by a second interchromosomal
exchange involving the same chromosome in the het-
erozygous mother, leading to the tandem triplication in
the child. It is unknown whether the presence of the first
microduplication predisposed to the second rearrange-
ment. Interestingly, the phenotype of this patient is very
mild. The patient’s mother has a microduplication of the
22q11.2 deletion syndrome region and a normal phe-
notype, except for dysmorphic hands, suggesting that
modifier loci in this family are ameliorating the effect of
the chromosomal defect.
To ascertain a significant proportion of 22q11.2
microduplications, a very large number of individuals
would need to be screened. However, microduplications
have generally been more difficult to detect than dele-
tions. Microduplications of 22q11.2 have previously
been diagnosed primarily using interphase FISH (Edel-
mann et al. 1999b; Ensenauer et al. 2003). Although
this method is effective, it is time-consuming and is not
suited for quickly screening large numbers of patients.
However, this technique does give unique information
about the position and arrangement of the duplicated
segments. In our study, FISH analysis of patient 4 re-
vealed that the two additional copies of the 22q11.2
deletion syndrome region are both located on the same
homologue, indicating a tandem triplication (fig. 3). Du-
plications of 22q11.2 have also previously been seen
by use of chromosome banding; however, a resolution
greater than what is routinely used was necessary (En-
senauer et al. 2003).
Microsatellite analysis has also been used to detect
22q11.2 microduplications and to define breakpoints
(Edelmann et al. 1999a; Ensenauer et al. 2003). How-
ever, because dosage analysis with microsatellites is, at
best, only semiquantitative, unambiguous results are
obtained only when the number of different allele sizes
is equal to the copy number of the region. Preferential
amplification of the smaller alleles leads to inaccuracies,
as do stuttering effects, which produce smaller peaks
preceding the major-allele peak (Armour et al. 2002).
However, in the case of patient 4, microsatellite analysis
gave unique information about possible mechanisms of
the formation of the triplication.
Real-time PCR (Thiel et al. 2003) and MAPH (Ar-
mour et al. 2000) are two methods used to study changes
in dosage that generally give unambiguous results and
only require a small amount of DNA from the patient.
Real-time PCR is a quick, straightforward, and repro-
ducible test that uses minute amounts of DNA. As many
as 185 patients can be analyzed in a single run for the
dosage (deletion or duplication) of one probe. The dis-
advantage of this technique is the cost of both the ini-
tial equipment and the individual probes. Alternatively,
MAPH was specifically designed to analyze a large num-
ber of probes at once and, therefore, is suited to more-
complex detection projects, such as breakpoint com-
parisons. In this study, we scanned for microduplications
over seven genes in the CES region, as well as single
genes within and distal to the 22q11.2 deletion syn-
drome region.
All four methods were used in our study, although not
all methods were used on each patient. All patients were
examined with more than one method, and, in each case,
the results concurred. Each technique has advantages and
disadvantages. However, for screening large numbers of
individuals, real-time PCR is the method of choice; mi-
croarray-based comparative genomic hybridization (array
CGH) has also been used to detect abnormalities of
22q11.2 (Mantripragada et al. 2004). Large screens of
different patient cohorts would aid in defining the full
phenotypic spectrum of the 22q11.2 microduplication
syndrome. The finding of 22q11.2 microduplications in
2 of 275 females who tested negative for fragile X syn-
drome implies that these microduplications are not un-
common and that they may be associated more with neu-
rological and behavioral features in many patients. The
remaining challenge is to identify these patients, and this
syndrome is likely to remain underdiagnosed until this is
done. Large-scale real-time PCR screens of neurologically
impaired individuals (those with developmental delay,
mild dysmorphology, minor behavioral problems, and
learning disabilities with mild dysmorphology), such as
diagnostic fragile X referrals, followed by family studies
to detect relatives with 22q11.2 microduplications, would
be a reasonable place to start. Indeed, our success rate
for detecting 22q11.2 microduplications among fragile X
referrals (0.7%) approaches half of the success rate for
detecting fragile X itself in this cohort (2%) and is twice
the number of 22q11.2 microduplications found in the
22q11.2 deletion syndrome referrals. By widening the
scope of the patients tested, we will gain a better under-
standing of the phenotype associated with 22q11.2
microduplications.
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